Psychopharmacology and Psychiatry Updates

265 Episoder

1. Association Between Mood Disorders and COVID-19

   Publisert: 16.6.2022
2. Antidepressants and Naltrexone for Stimulant Use Disorder

   Publisert: 11.6.2022
3. CANMAT Task Force Recommendations for the Use of Ketamine

   Publisert: 6.6.2022
4. Stimulant Replacement Therapies for Methamphetamine and Amphetamine Use Disorder

   Publisert: 1.6.2022
5. Premenstrual Mood Syndromes

   Publisert: 27.5.2022
6. Stimulant Use Disorder: Diagnosis and Assessment

   Publisert: 22.5.2022
7. Zuranolone for Postpartum Depression

   Publisert: 17.5.2022
8. Long-Term Treatment of First Episode of Psychosis

   Publisert: 12.5.2022
9. The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia

   Publisert: 7.5.2022
10. Health Issues in First Episode of Psychosis

    Publisert: 2.5.2022
11. Psychopharmacology for Treatment-Resistant Early Psychosis

    Publisert: 27.4.2022
12. Assessing and Treating Adult ADHD

    Publisert: 22.4.2022
13. Medications for Binge Eating Disorder

    Publisert: 17.4.2022
14. Antipsychotics for First Episodes of Psychosis

    Publisert: 12.4.2022
15. Effects on Suicidal Risk With Different Medications

    Publisert: 7.4.2022
16. Risks of Using Cannabinoids

    Publisert: 2.4.2022
17. Lithium: How to Manage Dosage

    Publisert: 28.3.2022
18. CBD as a Medication

    Publisert: 23.3.2022
19. SSRIs and Suicidality

    Publisert: 18.3.2022
20. Cannabis and Cognition

    Publisert: 13.3.2022